Kirkland & Ellis advised Amicus Therapeutics (Nasdaq: FOLD) on its agreed all-cash sale to BioMarin (Nasdaq: BMRN) at $14.50 per share, valuing Amicus at about $4.8bn.
The deal was unanimously approved by both boards, with Amicus’ board recommending stockholders vote in favour; expected to close in Q2 2026, subject to regulatory and Amicus stockholder approvals and other customary conditions.
The acquisition adds Galafold (Fabry) and Pombiliti + Opfolda (Pompe) to BioMarin’s lysosomal storage disorder portfolio, and includes Amicus’ U.S. rights to DMX-200 (Phase 3) for FSGS.
Generated by AI, original source from - Data is in progress
Found it useful? Spread the word.
Kirkland & Ellis advises Amicus Therapeutics on $4.8 billion sale to BioMarin | The Sponsor - The Sponsor
